This is a working overview of peptide analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
== External links == GeneReviews/NCBI/NIH/UW entry on Aceruloplasminemia OMIM entries on Aceruloplasminemia Overview of all the structural information available in the PDB for UniProt: P00450 (Human Ceruloplasmin) at the PDBe-KB.
Songbirds, parrots, and other species are popular as pets. Guano (bird excrement) is harvested for use as a fertiliser. Birds figure throughout human culture. About 120 to 130 species have become extinct due to human activity since the 17th century, and hundreds more before then. Human activity threatens about 1,200 bird species with extinction, though efforts are underway to protect them. Recreational birdwatching is an important part of the ecotourism industry.
== Chemical reaction == The two substrates of this enzyme are the luciferin, coelenterazine and oxygen. Its products are the oxyluciferin, coelenteramide, carbon dioxide, and a photon. It belongs to the family of oxidoreductases, specifically those acting on single donors with O2 as oxidant and initial incorporation of two atoms of oxygen into the substrate. Although the enzyme is part of the group of enzymes that act on coelenterazine, such as Renilla and Gaussia luciferases, it does not share base pair sequences with these enzymes. OpLuc catalyzes the ATP independent chemical reaction:
Sources: en.wikipedia.org
== Background == Chlorobactene is a monocyclic accessory pigment used by green sulfur bacteria to capture electrons from wavelengths in the visible light spectrum. Green sulfur bacteria (GSB) live in anaerobic and sulfidic (euxinic) zones in the presence of light, so they are found most often in meromictic lakes and ponds, sediments, and certain regions of the Black Sea. The enzyme CrtU converts γ-carotene into chlorobactene by shifting the C17 methyl group from the C1 site to the C2 site.
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\nu N(1-P)-\mu S-\beta {\frac {I}{N}}S\\[8pt]{\frac {dI}{dt}}&=\beta {\frac {I}{N}}S-(\mu +\gamma )I\\[8pt]{\frac {dV}{dt}}&=\nu NP-\mu V\end{aligned}}}
25 October – 485 people affiliated with the environmental group Bream Bay Guardians build sand sculptures to protest against a fast-tracked sand mining proposal in Bream Bay. 26 October: Police arrest an 18-year old Dunedin man in relation to a bomb threat against the Wellington Islamic Centre in Kilbirnie. Health NZ confirms a measles case at Wellington Girls' College. Four staff and 60 students are identified as possible contacts of the patient. 27 October: Two new measles cases are reported in Wellington, bringing the total number of cases to 10. One case were linked to international travel while seven were linked to a "high-risk exposure event" on a Bluebridge ferry on 3 October. Health NZ identifies several hundred close contacts at Wellington College. Waatea News reports that Te Pāti Māori members had voted to recommend the suspension of MP Mariameno Kapa-Kingi and that the Te Tai Tokerau electorate executive be "reset" at a meeting on 23 October. The New Zealand Government contributes NZ$150,000 to mayoral relief funds in Southland and Clutha District to assist with post-windstorm damage. Chinese citizens transiting through New Zealand become eligible for the New Zealand Electronic Travel Authority (NZETA). 28 October: The Labour Party unveils its capital gains tax policy to fund doctors' visits. Education Minister Erica Stanford releases the Government's full draft curriculum for Years 0–10 students for consultation. A power outage at a waste treatment plant in Warkworth contaminates oyster farms in the Mahurangi River.
Sources: en.wikipedia.org
=== Adenovirus and cytomegalovirus === As of 2014, brincidofovir is in Phase III clinical trials for use in humans against cytomegalovirus and adenovirus. Preliminary safety data from a database of 1000 patients supported progression into later phase trials, Chimerix announced in December 2015 that the Phase III trials for use of the drug in preventing cytomegalovirus infection in stem cell transplant patients had failed, and in February 2016 shut down two other late-stage trials for use of the drug in preventing infection after kidney transplants. Brincidofovir is not yet FDA approved for adenovirus or cytomegalovirus due to lack of efficacy in clinical trials. In a trial of brincidofovir for CMV prophylaxis in stem cell transplant patients, brincidofovir was associated with a 15.5% week 24 all-cause mortality compared with 10.1% among placebo recipients. Additionally brincidofovir was associated with increased serious adverse events (57.1% versus 37.6%) compared with placebo. Brincidofovir was initially offered via an FDA expanded access trial; however as of 9 May 2019, Chimerix discontinued clinical trials of brincidofovir for the treatment of adenovirus and discontinued the expanded access program in 2019.
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) intended to modulate the behavior of immune cells in cases of neurodegenerative disease such that they protect dopamine-producing cells rather than attack them. The drug is currently being studied for its potential use in the treatment of Parkinson's disease.
Leaning heavily into European free improvisation and avant-garde classical structures, the line-up eventually stripped down to a core trio of Fripp, Bruford, and Wetton, producing the highly acclaimed studio albums Larks' Tongues in Aspic (1973), Starless and Bible Black (1974), and Red (1974), before Fripp temporarily disbanded the group. King Crimson returned from a seven-year hiatus in 1981 with a revamped, transatlantic line-up featuring Fripp, Bruford, and American musicians Adrian Belew and Tony Levin. Incorporating elements of New York minimalism, gamelan, and contemporary new wave, this iteration recorded a distinct trilogy of studio albums: Discipline (1981), Beat (1982), and Three of a Perfect Pair (1984). After another decade-long dormancy, the band reconstituted in 1994 as a "Double Trio" sextet, adding Pat Mastelotto and Trey Gunn to release Thrak (1995). During the late 1990s, the band members also operated in smaller, improvised sub-groups known as "ProjeKcts". The main group continued into the early 2000s as a quartet, releasing The ConstruKction of Light (2000) and The Power to Believe (2003), which showcased a heavier, industrial-influenced sound. Following a brief 40th-anniversary tour in 2008 that introduced drummer Gavin Harrison, Fripp placed the group on hold until 2013. King Crimson then re-emerged as a highly structured touring septet (and later octet) featuring an unusual three-drummer frontline and lead vocalist Jakko Jakszyk.
== Education == Uhlmann was educated at the University of Tübingen where he was awarded a PhD in 1997. During his PhD, he worked with Jerard Hurwitz at the Memorial Sloan Kettering Cancer Center in New York City.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.